PDL BioPharma, Inc. (PDLI1)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
John Peter McLaughlin
Employees:
297
932 SOUTHWOOD BLVD, INCLINE VILLAGE, NV 89451
775-832-8500

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

PDL BioPharma, Inc. produces and markets biopharmaceutical products. It focuses on intellectual property asset management, investing in new royalty bearing assets and maximizing the value of its patent portfolio and related assets. The company manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. PDL BioPharma was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Incline Village, NV.

Data derived from most recent annual or quarterly report
Market Cap 282.14 Million Shares Outstanding114.227 Million Avg 30-day Volume 4.704 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.59
Price to Revenue12.5222 Debt to Equity0.0459 EBITDA-35.695 Million
Price to Book Value0.649 Operating Margin-166.2807 Enterprise Value243.304 Million
Current Ratio6.87 EPS Growth-0.255 Quick Ratio4.993
1 Yr BETA 0.7381 52-week High/Low 0.0 / Profit Margin-229.9493
Operating Cash Flow Growth-172.7074 Altman Z-Score3.4457 Free Cash Flow to Firm 389.146 Million
View SEC Filings from PDLI1 instead.

View recent insider trading info

Funds Holding PDLI1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PDLI1 BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SILVER POINT CAPITAL L.P.

O'SHEA ROBERT J

MULE EDWARD A

  • 10% Owner
23,970,334 2021-02-01 0

GRYSKA DAVID W

  • Director
1,387 2020-12-30 0

PARK WEST ASSET MANAGEMENT LLC

  • 10% Owner
14,397,212 2020-12-30 0

MCLAUGHLIN JOHN PETER

  • Director
200,000 2020-12-21 0

STONE CHRISTOPHER LEWIS VP, GEN. COUNSEL & SECRETARY

  • Officer
405,559 2020-12-16 0

MONNET DOMINIQUE PRESIDENT AND CEO

  • Officer
734,921 2020-12-16 0

O'FARRELL ELIZABETH G.

  • Director
0 2020-11-23 0

BAZAAR ALAN LEE

  • Director
10,438 2020-11-18 0

HERNDAY NATASHA

  • Director
75,826 2020-08-19 0

IMBROGNO EDWARD VP FINANCE, CAO AND ACTING CFO

  • Officer
232,077 2020-02-07 0

JENE JILL M. VP, BUSINESS DEVELOPMENT

  • Officer
194,805 2020-01-08 0

SANDMAN PAUL W

  • Director
0 2019-06-20 0

SELICK HAROLD E

  • Director
0 2019-06-20 0

SAKS SAMUEL R

  • Director
0 2019-06-20 0

YANAI SHLOMO

  • Director
0 2019-06-20 0

GARCIA PETER S VICE PRESIDENT, CFO

  • Officer
0 2019-03-28 0

LINDELL JODY S

  • Director
256,174 2018-06-08 0

EDICK PAUL R

  • Director
214,563 2018-06-08 0

PIETZKE STEFFEN VP, FINANCE AND CAO

  • Officer
160,177 2017-12-15 0

HART DANNY J JR. VP BUSINESS DEVELOPMENT

  • Officer
387,236 2017-03-04 0

IMMUNE RESPONSE BIOPHARMA, INC.

  • SHAREHOLDER
1 2015-05-17 0

MONTEZ DAVID CONTROLLER AND CAO

  • Officer
26,719 2015-01-28 0

TOMLINSON BRUCE CHIEF FINANCIAL OFFICER

  • Officer
16,509 2012-06-21 0

FRANK FRED

  • Director
33,296 2012-06-05 0

KRUMEL CAROLINE J VPFINANCE/PRIN.ACCTING OFFICER

  • Officer
9,384 2012-01-18 0

LARSON CHRISTINE R VICE PRESIDENT AND CFO

  • Officer
62,049 2011-05-23 0

KLEIN JOSEPH III

  • Director
16,994 2009-11-04 0

WILSON KAREN J VP OF FINANCE & PAO

  • Officer
10,494 2009-05-07 0

GUGGENHIME ANDREW SVP & CHIEF FINANCIAL OFFICER

  • Officer
No longer subject to file 2008-12-18 0

MCCAMISH MARK ANTHONY SVP & CMO

  • Officer
No longer subject to file 2008-12-18 0

CROSS HERB CORP CONTROLLER/PRIN ACCTG OFF

  • Officer
5,031 2008-09-15 0

SARENA FRANCIS WILLARD VP/GEN COUNSEL/SECY

  • Officer
5,756 2008-09-15 0

LYONS GARY A

  • Director
0 2008-08-13 0

HORA MANINDER VP OF PRODUCT OPERATIONS

  • Officer
4,657 2008-08-13 0

MURRAY RICHARD /CA/ EVP & CSO

  • Officer
70,159 2008-07-21 0

GOODWIN BRADFORD S CHAIRPERSON OF THE BOARD

  • Officer
  • Director
0 2008-07-16 0

KORN LAURENCE JAY

  • Director
0 2008-05-28 0

DAWES KAREN A CHAIRPERSON OF THE BOARD

  • Officer
  • Director
2,250 2008-04-29 0

GAGE L PATRICK INTERIM CEO

  • Officer
  • Director
19,555 2008-04-28 0

SHAH JAISIM SVP, MKTG & BUS. AFFAIRS

  • Officer
16,125 2008-04-28 0

SAXE JON S

  • Director
421,680 2008-04-09 0

IWANICKI DAVID VP, SALES & SALES OPERATIONS

  • Officer
0 2008-01-02 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
FundVantage Trust- Gotham Enhanced Index Plus Fund PDLI1 -20.0 shares, $-56.4 2020-03-31 N-PORT
FundVantage Trust- Gotham Index Plus All-Cap Fund PDLI1 -34.0 shares, $-95.88 2020-03-31 N-PORT
iShares Trust- iShares Russell 2000 Value ETF PDLI1 -1188.0 shares, $-2200.77 2021-12-31 N-PORT
iShares Trust- iShares Biotechnology ETF PDLI1 -4374.0 shares, $-8102.84 2021-12-31 N-PORT
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund PDLI1 -4500.0 shares, $-11115.0 2021-12-31 N-PORT

Elevate your investments